Apr 20, 2016

Posted by in Biotech Stocks | 0 Comments

Stocks Under Review: Repros Therapeutics Inc (NASDAQ:RPRX), Illumina Inc (NASDAQ:ILMN), Gilead Sciences Inc (NASDAQ:GILD)

Stocks Under Review: Repros Therapeutics Inc (NASDAQ:RPRX), Illumina Inc (NASDAQ:ILMN), Gilead Sciences Inc (NASDAQ:GILD)

Repros Therapeutics Inc (NASDAQ:RPRX) surged +12.19% and ended at $3.13. The total traded volume was 17.82 million shares and market capitalization arrived at $93.55 million. The stock has a 52-week high price of $8.96 and its 52-week low was recorded at $0.80, while during last trade its minimum price was $2.86 and it gained the highest price of $3.45.

Repros Therapeutics Inc (NASDAQ:RPRX) on April 12, 2016 reported that vaginal administration of Proellex® at doses of both 6 and 12 mg achieved significant reduction in excessive menstrual bleeding, the key symptom of uterine fibroids.

Normal menstrual blood loss in a menstrual cycle is approximately 35 mL. Woman experiencing blood loss of >80 mL are considered to suffer from menorrhagia or excessive menstrual bleeding. In this small Phase 2b study, 13, 15 and 14 women with confirmed uterine fibroids were enrolled in the 6mg, 12mg and placebo arms, respectively. At baseline, the mean amount of blood lost for one menstrual cycle was 255 mL, 274 mL and 238 mL for each arm, respectively. The blood loss ranged from a low of 94 mL to a high of 654 mL. The most severe menstrual bleeding at baseline was observed in the 12 mg group. Blood loss was determined by collecting all sanitary products used from an individual and then an alkaline hematin assay was performed to estimate the actual amount of blood collected in the pads.

When a sufficient concentration of Proellex® is achieved in circulation, amenorrhea (cessation of menses) is achieved. Just over half, 52%, of Proellex®-treated subjects became amenorrheic with no evidence of a dose effect. All subjects treated with Placebo continued to menstruate throughout the 18 week dosing period. The p-value for this comparison is 0.0011.  Bleeding diaries consistently report a statistically significant difference in the number of days of bleeding and bleeding intensity between those treated with Proellex® and Placebo.

Bleeding was also evaluated by PBAC (Pictorial Blood Assessment Chart).  Subjects tallied sanitary product usage and stain size as guided by the chart.  Proellex®-treated subjects reported a median 100% reduction in PBAC scores while Placebo-treated subjects reported a 25.4% reduction, further supporting the treatment affect associated with bleeding (p=0.0033).

Along with changes in menstrual patterns, fibroids measured by MRI were reduced in volume in the Proellex®-treated arms by 18% while the Placebo group showed continued increase in size, p= 0.0437.

The drug was generally well tolerated. Women in the drug arms continued to exhibit levels of estradiol consistent with bone preservation.

Illumina Inc (NASDAQ:ILMN) reported the decrease of -23.16% to close at $136.88 with the overall traded volume of 11.38 million shares. Its market capitalization on last close reached to $20.65 billion. Its beta value stands at 0.84 times. The company has the total of 147.08 million outstanding shares. Its intraday-low price was $132.51 and its hit its day’s highest price at $144.00.

Illumina Inc (NASDAQ:ILMN) on April 18, 2016 announced estimated first quarter revenue of approximately $572 million, a 6% increase compared to $539 million in the first quarter of 2015 and 7% growth on a constant currency basis. This estimate, which is unaudited, is based on management’s preliminary financial analysis.

“Our first quarter results fell short of expectations largely due to lower than expected sales of HiSeq 2500, 3000 and 4000 instruments. Despite this slow start in Q1, we anticipate that our Americas and Asia Pacific regions will meet our expectations for the full year, but that Europe will underperform. As a result, we now project approximately 12% revenue growth for fiscal 2016,” stated Jay Flatley, Chairman and CEO. “Given the disappointing outlook in Europe, we have made management changes in the region and plan to implement a program of actions to achieve our goal of delivering the robust growth we believe the market can support.”

Gilead Sciences Inc (NASDAQ:GILD) moved up +0.24% to settle at $99.44. Its total traded volume during last trading session was 9.81 million shares. The overall market worth of this company is about $135.95 billion. The 52 week range of the stock remained $81.89 – $123.37, while its day’s lowest price was $99.24 and its hit its day’s highest price at $100.73. The beta of this stock currently stands at 1.03.

Gilead Sciences Inc (NASDAQ:GILD) on April 16, 2016 announced data supporting the development of three investigational agents for the treatment of nonalcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC). The data were presented in oral and poster sessions at The International Liver CongressTM 2016 in Barcelona, Spain.

NASH is a serious liver disease resulting from metabolic dysfunction that is associated with steatosis (fat within the liver), inflammation and fibrosis, which may progress to cirrhosis. NASH-related cirrhosis is expected to become the leading indication for liver transplantation by 2020. PSC is a disease characterized by inflammation and stricturing of the bile ducts. PSC can eventually lead to cirrhosis and other complications, including bile duct cancer.

 

Comments are closed.